Supramolecular lipidic drug delivery systems: From laboratory to clinic A review of the recently introduced commercial liposomal and lipid-based formulations of amphotericin B
- 1 March 1997
- journal article
- review article
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 24 (2-3) , 345-363
- https://doi.org/10.1016/s0169-409x(96)00496-6
Abstract
No abstract availableKeywords
This publication has 83 references indexed in Scilit:
- Stability of liposomes invivo and invitro is promoted by their cholesterol content and the presence of blood cellsPublished by Elsevier ,2004
- Lipid Formulations of Amphotericin BDrug Safety, 1995
- Liposomes in Drug DeliveryDrugs, 1993
- Cost-Effectiveness Analysis of Treatment with Liposomal Amphotericin B versus Conventional Amphotericin B in Organ or Bone Marrow Transplant Recipients with Systemic MycosesPharmacoEconomics, 1992
- Liposomal and Lipid Formulations of Amphotericin BClinical Pharmacokinetics, 1992
- Fungal infections in cancer patients: An international autopsy surveyEuropean Journal of Clinical Microbiology & Infectious Diseases, 1992
- Inhibition of the interaction between lipoproteins and amphotericin B by some delivery systemsBiochemical and Biophysical Research Communications, 1991
- Amphotericin B NephrotoxicityDrug Safety, 1990
- Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infectionsEuropean Journal of Cancer and Clinical Oncology, 1988
- Application of liposomes to the pharmaceutical modification of the distribution characteristics of drugs in the rat.CHEMICAL & PHARMACEUTICAL BULLETIN, 1975